{
  "doc_id": "946ecafb651b0489de97bcd250d7e2b2be78548676637e773a16433a4fa37a2d",
  "chunk_entities": [
    {
      "chunk_id": "920d282bfa000356cf0f018ee2fd8827",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 4 inhibitors",
          "context": "Phosphodiesterase 4 inhibitors and drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "Phosphodiesterase 4 inhibitors and drugs of abuse"
        }
      ]
    },
    {
      "chunk_id": "2b1b0fb78e7bf9d3917894168b0d5e5b",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "up-regulation of the cAMP-signaling pathway"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug tolerance",
          "context": "aspects of drug tolerance"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "and dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "exposure to drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 4",
          "context": "Phosphodiesterase 4 (PDE4) is an enzyme"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinforcing effects",
          "context": "regulate the reinforcing effects"
        }
      ]
    },
    {
      "chunk_id": "aeed08f92815866e113bc2e79743ce0f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "PDE4 is a cAMP-specific phosphodiesterase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "cAMP-specific phosphodiesterase"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reinforcing effects",
          "context": "regulates the reinforcing effects of drugs of abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drugs of abuse",
          "context": "reinforcing effects of drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP",
          "context": "neuroadaptations in cyclic AMP (cAMP) signaling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug tolerance",
          "context": "underlie aspects of drug tolerance and dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "drug tolerance and dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 inhibitors reduce drug intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce drug intake",
          "context": "PDE4 inhibitors reduce drug intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug seeking",
          "context": "and/or drug seeking for psychostimulants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "drug seeking for psychostimulants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "psychostimulants, alcohol, and opioids"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioids",
          "context": "alcohol, and opioids"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorder",
          "context": "therapeutic target for several classes of substance use disorder"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-addictive behavioral effects",
          "context": "anti-addictive behavioral effects of PDE4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase in intracellular cAMP levels",
          "context": "widespread increase in intracellular cAMP levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 isoforms",
          "context": "CNS) distribution of PDE4 isoforms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of PDE4",
          "context": "specific inhibition of PDE4 on behavioral models"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "behavioral models of drug addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "non-selective PDE4 inhibitors",
          "context": "potential of non-selective PDE4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce addiction liability",
          "context": "may reduce addiction liability"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction liability",
          "context": "may reduce addiction liability"
        },
        {
          "entity_type": "Effect",
          "entity_name": "minimize the side effects",
          "context": "and minimize the side effects"
        }
      ]
    },
    {
      "chunk_id": "70c87099b86a655798c3ca681fc97782",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterases (PDEs)",
          "context": "Phosphodiesterases (PDEs) are a family of enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "hydrolyze intracellular cAMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cGMP",
          "context": "hydrolyze intracellular cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE1",
          "context": "PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE2",
          "context": "PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE3",
          "context": "PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "PDE4, PDE7, and PDE8 are specific for cAMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE7",
          "context": "PDE4, PDE7, and PDE8 are specific for cAMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE8",
          "context": "PDE4, PDE7, and PDE8 are specific for cAMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE5",
          "context": "PDE5, PDE6, and PDE9 are specific for cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE6",
          "context": "PDE5, PDE6, and PDE9 are specific for cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE9",
          "context": "PDE5, PDE6, and PDE9 are specific for cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE10",
          "context": "PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE11",
          "context": "PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance abuse",
          "context": "treatment of substance abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "substance use disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 and PDE4 inhibitors"
        }
      ]
    },
    {
      "chunk_id": "fe183cdf2221319e24cc3d6ab0fc6c69",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 isoforms",
          "context": "PDE4 isoforms"
        }
      ]
    },
    {
      "chunk_id": "ecad62b522b0b291519e8b5fe3d6fadc",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B mRNA",
          "context": "PDE4B mRNA is high in the human and rodent striatum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4A mRNA",
          "context": "PDE4A and PDE4D mRNA levels are present in lower amounts"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D mRNA",
          "context": "PDE4A and PDE4D mRNA levels are present in lower amounts"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B protein",
          "context": "PDE4B-immunopositive neurons and neuropil are observed"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B",
          "context": "PDE4B is differentially expressed in two major, functionally distinct subpopulations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D1 receptor",
          "context": "dopamine D1 receptor-expressing \u201cdirect\u201d (striatonigral) output pathway"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D2 receptor",
          "context": "dopamine D2 receptor-expressing \u201cindirect\u201d (striatopallidal) output pathway"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "dopamine D1 receptor-expressing \u201cdirect\u201d (striatonigral) output pathway"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behaviorally stimulating",
          "context": "the direct pathway is behaviorally stimulating"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behaviorally suppressant",
          "context": "the indirect pathway is behaviorally suppressant"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B protein",
          "context": "PDE4B protein is also abundant in the ventral pallidum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "selectively bred alcohol preferring rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4A mRNA",
          "context": "PDE4A mRNA was elevated and PDE4B2 mRNA was reduced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B2 mRNA",
          "context": "PDE4B2 mRNA was reduced in the accumbens"
        }
      ]
    },
    {
      "chunk_id": "7b9af0fbb00b3348fc67553bb9d80568",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 isoforms",
          "context": "measuring PDE4 isoforms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D mRNA",
          "context": "PDE4D mRNA was the highest"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B",
          "context": "while 4B was lower"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4A",
          "context": "and 4A was not detected"
        }
      ]
    },
    {
      "chunk_id": "1a0f027a9bfa2d7c8372f363fd5cebb4",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "saline",
          "context": "after a saline infusion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "after a cocaine infusion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "flumazenil",
          "context": "pretreatment with flumazenil"
        },
        {
          "entity_type": "Compound",
          "entity_name": "benzodiazepine",
          "context": "antagonist of the benzodiazepine binding site"
        },
        {
          "entity_type": "Compound",
          "entity_name": "diazepam",
          "context": "reduces the percentage of diazepam-appropriate responses"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "treatment with amphetamine"
        }
      ]
    },
    {
      "chunk_id": "2ef34a1ed1be70250b108ff951406441",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "Although PDE4 inhibitors are known"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhance cognitive functions",
          "context": "known to enhance cognitive functions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "learning",
          "context": "such as learning and memory"
        },
        {
          "entity_type": "Effect",
          "entity_name": "memory",
          "context": "learning and memory"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cognitive decline",
          "context": "pharmacotherapy of cognitive decline"
        }
      ]
    },
    {
      "chunk_id": "f839d290fbab0107b416294971036ff4",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "Methamphetamine: Beardsley and coworkers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PDE inhibitor",
          "context": "non-selective PDE inhibitor ibudilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "PDE inhibitor ibudilast and its analogs"
        },
        {
          "entity_type": "Disease",
          "entity_name": "methamphetamine abuse",
          "context": "on methamphetamine abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "effects on cocaine-associated hyperlocomotion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperlocomotion",
          "context": "cocaine-associated hyperlocomotion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "ibudilast and its analog AV1013"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AV1013",
          "context": "ibudilast and its analog AV1013"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce the methamphetamine-induced increase in locomotor activity",
          "context": "reduce the methamphetamine-induced increase in locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sensitization",
          "context": "locomotor activity and sensitization"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affecting locomotor activity",
          "context": "significantly affecting locomotor activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "ibudilast and AV1013 are effective"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AV1013",
          "context": "ibudilast and AV1013 are effective"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuating methamphetamine self-administration",
          "context": "attenuating methamphetamine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug seeking behavior",
          "context": "and drug seeking behavior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces methamphetamine self-administration",
          "context": "reduces methamphetamine self-administration on an FR1 schedule"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "Systemic ibudilast and AV1013"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AV1013",
          "context": "Systemic ibudilast and AV1013"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces footshock- and prime-induced reinstatement of methamphetamine-seeking",
          "context": "reduces footshock- and prime-induced reinstatement of methamphetamine-seeking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction of drug seeking behavior",
          "context": "the reduction of drug seeking behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "by ibudilast and its analog"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inflammatory processes",
          "context": "associated with inflammatory processes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "Methamphetamine activates glial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "activates glial cells",
          "context": "activates glial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases proinflammatory cytokine production",
          "context": "increases proinflammatory cytokine production in the brain"
        },
        {
          "entity_type": "Effect",
          "entity_name": "glial cell activation",
          "context": "glial cell activation and inflammatory responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inflammatory responses",
          "context": "and inflammatory responses have been linked"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug abuse-related behavior",
          "context": "linked to drug abuse-related behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ibudilast",
          "context": "Ibudilast inhibits both PDE"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits PDE",
          "context": "inhibits both PDE and glial proinflammatory activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "glial proinflammatory activity",
          "context": "and glial proinflammatory activity"
        }
      ]
    },
    {
      "chunk_id": "d715fd883cc9d85eb2d357cb456f6fa8",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "AV1013",
          "context": "AV1013 shares the anti-inflammatory activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory activity",
          "context": "shares the anti-inflammatory activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "activity of ibudilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE",
          "context": "negligibly inhibits PDE"
        },
        {
          "entity_type": "Effect",
          "entity_name": "glial inflammatory activity",
          "context": "modulation of glial inflammatory activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuation",
          "context": "contributes to the attenuation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "methamphetamine-induced locomotor sensitization",
          "context": "attenuation of methamphetamine-induced locomotor sensitization"
        },
        {
          "entity_type": "Effect",
          "entity_name": "relapse of drug seeking",
          "context": "relapse of drug seeking by ibudilast"
        },
        {
          "entity_type": "Disease",
          "entity_name": "methamphetamine abuse",
          "context": "treating methamphetamine abuse"
        }
      ]
    },
    {
      "chunk_id": "0bc25299772f1d7d19378a920b823f62",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Alcohol",
          "context": "Alcohol: Regulation of alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDEs",
          "context": "subtypes of PDEs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol drinking",
          "context": "Regulation of alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "behavioral effects of PDE4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral effects",
          "context": "studying behavioral effects of PDE4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol drinking",
          "context": "inhibitors on alcohol drinking"
        }
      ]
    },
    {
      "chunk_id": "9e438a2ab71427981a77ff504eca50bc",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "Reduction of alcohol drinking by PDE4 inhibitors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol drinking",
          "context": "Reduction of alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "access to alcohol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Rolipram",
          "context": "Rolipram and Ro 20-1724"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ro 20-1724",
          "context": "Rolipram and Ro 20-1724"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce alcohol intake and preference",
          "context": "Rolipram and Ro 20-1724 reduce alcohol intake and preference"
        },
        {
          "entity_type": "Compound",
          "entity_name": "sucrose",
          "context": "intake of sucrose"
        },
        {
          "entity_type": "Compound",
          "entity_name": "quinine",
          "context": "intake of sucrose or quinine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol-induced sedation",
          "context": "alcohol-induced sedation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alcohol metabolism",
          "context": "or alcohol metabolism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol drinking",
          "context": "animal models of alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "Acute administration of rolipram"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces operant self-administration of alcohol",
          "context": "dose-dependently reduces operant self-administration of alcohol"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases 2-bottle choice alcohol consumption and preference",
          "context": "chronic rolipram treatment decreases 2-bottle choice alcohol consumption and preference"
        }
      ]
    },
    {
      "chunk_id": "b4d61aa725cb159fe54c87b64295c5f8",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "The non-selective phosphodiesterase inhibitor ibudilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces 2-bottle choice alcohol drinking",
          "context": "ibudilast reduces 2-bottle choice alcohol drinking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces relapse",
          "context": "alcohol drinking and relapse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol-preferring",
          "context": "alcohol-preferring P rats"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol-dependent",
          "context": "in alcohol-dependent C57BL/6J mice"
        },
        {
          "entity_type": "Effect",
          "entity_name": "had no effect on alcohol drinking",
          "context": "doses which had no effect on alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE inhibitors",
          "context": "PDE inhibitors reduce alcohol drinking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce alcohol drinking",
          "context": "PDE inhibitors reduce alcohol drinking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "models of genetic susceptibility and dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ibudilast",
          "context": "ibudilast is a non-selective PDE inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE inhibitor",
          "context": "non-selective PDE inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "inhibitors to other PDE subtypes",
          "context": "inhibitors to other PDE subtypes reduce alcohol drinking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce alcohol drinking",
          "context": "PDE subtypes reduce alcohol drinking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "alcohol drinking and dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE inhibitors",
          "context": "effects of nine PDE inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selective PDE4 inhibitors",
          "context": "only the selective PDE4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce ethanol intake",
          "context": "PDE4 inhibitors reduce ethanol intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce preference",
          "context": "ethanol intake and preference"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TP-10",
          "context": "the PDE10A inhibitor TP-10"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces alcohol self-administration",
          "context": "TP-10 reduces alcohol self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TP-10",
          "context": "TP-10 also reduces alcohol self-administration"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol-preferring",
          "context": "genetically alcohol-preferring rats"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol-non-dependent",
          "context": "alcohol-non-dependent and -dependent rats"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol-dependent",
          "context": "alcohol-non-dependent and -dependent rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "PDE4 and PDE10A are potential therapeutic targets"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE10A",
          "context": "PDE4 and PDE10A are potential therapeutic targets"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol dependence",
          "context": "pharmacotherapy of alcohol dependence"
        }
      ]
    },
    {
      "chunk_id": "b89d713905ece27bb27ff3436679ae21",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Opioids",
          "context": "Opioids: PDE4 inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 inhibitors reduce morphine-induced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine-induced hyperlocomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperlocomotor activity",
          "context": "morphine-induced hyperlocomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "CPP",
          "context": "activity and CPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "injections of rolipram suppresses"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "morphine-induced hyperlocomotion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperlocomotion",
          "context": "morphine-induced hyperlocomotion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "administration of rolipram 30 min"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "30 min",
          "context": "rolipram 30 min prior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "blocks the acquisition of CPP",
          "context": "blocks the acquisition of CPP to morphine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "CPP",
          "context": "acquisition of CPP to morphine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "CPP to morphine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "administration of rolipram 30 min"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "30 min",
          "context": "rolipram 30 min prior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "CPP",
          "context": "expression of morphine CPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "expression of morphine CPP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE inhibitor",
          "context": "The PDE inhibitor rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "PDE inhibitor rolipram also inhibits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "discriminative-stimulus effects",
          "context": "inhibits the discriminative-stimulus effects of morphine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "effects of morphine in rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "the cAMP signaling cascade"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioned morphine reward",
          "context": "acquisition of conditioned morphine reward"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "conditioned morphine reward"
        }
      ]
    },
    {
      "chunk_id": "53b94c741b1bf38dd8ab9587398b6fc0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "The PDE4 inhibitor rolipram"
        },
        {
          "entity_type": "Effect",
          "entity_name": "does not significantly inhibit heroin self-administration",
          "context": "rolipram does not significantly inhibit heroin self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "inhibit heroin self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dose-dependently decreases the reward values",
          "context": "but dose-dependently decreases the reward values"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases the cue- and heroin priming-induced reinstatement of heroin seeking",
          "context": "rolipram also decreases the cue- and heroin priming-induced reinstatement of heroin seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "heroin priming-induced reinstatement"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin seeking",
          "context": "reinstatement of heroin seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "Rolipram increases the expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases the expression of phosphorylated CREB",
          "context": "Rolipram increases the expression of phosphorylated CREB"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphorylated CREB",
          "context": "expression of phosphorylated CREB"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin-seeking behavior",
          "context": "effect on heroin-seeking behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "that PDE4 inhibitors may be"
        },
        {
          "entity_type": "Effect",
          "entity_name": "treatment of heroin and morphine dependence",
          "context": "for the treatment of heroin and morphine dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "treatment of heroin and morphine dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "heroin and morphine dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heroin and morphine dependence",
          "context": "treatment of heroin and morphine dependence"
        }
      ]
    },
    {
      "chunk_id": "9eb6f4d54e0030fe9bdf47faf190909e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 inhibitors were shown to attenuate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "naloxone",
          "context": "attenuate naloxone-precipitated morphine withdrawal symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "naloxone-precipitated morphine withdrawal symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuate",
          "context": "attenuate naloxone-precipitated morphine withdrawal symptoms"
        },
        {
          "entity_type": "Disease",
          "entity_name": "morphine withdrawal symptoms",
          "context": "naloxone-precipitated morphine withdrawal symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "increase in PDE4 activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP",
          "context": "cyclic AMP was significantly increased"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "levels of cAMP, which may be involved"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "PDE4 inhibitors rolipram dampen naloxone-precipitated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dampen",
          "context": "rolipram dampen naloxone-precipitated behavioral signs"
        },
        {
          "entity_type": "Disease",
          "entity_name": "morphine withdrawal",
          "context": "behavioral signs of morphine withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "teeth-chattering",
          "context": "such as teeth-chattering"
        },
        {
          "entity_type": "Disease",
          "entity_name": "tremor",
          "context": "tremor"
        },
        {
          "entity_type": "Disease",
          "entity_name": "piloerection",
          "context": "piloerection"
        },
        {
          "entity_type": "Disease",
          "entity_name": "lacrimation",
          "context": "lacrimation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "rhinorrhea",
          "context": "rhinorrhea"
        },
        {
          "entity_type": "Disease",
          "entity_name": "ptosis",
          "context": "ptosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "spontaneous jumping",
          "context": "spontaneous jumping"
        },
        {
          "entity_type": "Disease",
          "entity_name": "wet-dog shakes",
          "context": "wet-dog shakes"
        },
        {
          "entity_type": "Disease",
          "entity_name": "weight loss",
          "context": "weight loss"
        },
        {
          "entity_type": "Disease",
          "entity_name": "withdrawal syndrome",
          "context": "attenuation of withdrawal syndrome"
        },
        {
          "entity_type": "Compound",
          "entity_name": "c-Fos protein",
          "context": "expression of c-Fos protein induced by naloxone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "blocked",
          "context": "blocked the increase in the expression"
        }
      ]
    },
    {
      "chunk_id": "a066a69009569bacd4df52d66c844bee",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "pharmacological intervention of drug addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "a number of PDE4 inhibitors have been approved"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "treatment of COPD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "inflammatory diseases",
          "context": "treatment of COPD and inflammatory diseases"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "repurpose these PDE4 inhibitors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "treatment of drug addiction"
        }
      ]
    },
    {
      "chunk_id": "4b1724b03dc618f80a443b41b0133ca0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 inhibitors such as rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "such as rolipram often cause nausea"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "often cause nausea and emesis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emesis",
          "context": "nausea and emesis, which prevent their clinical utility"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emetic effects",
          "context": "The emetic effects are likely mediated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "mediated by PDE4 expressed in the area postrema"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4A",
          "context": "PDE4A is predominantly expressed"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4B",
          "context": "PDE4B is highly expressed"
        }
      ]
    },
    {
      "chunk_id": "18d0a3ebb78da87a3fd540300a17dbe6",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "vomit",
          "context": "Why can't rodents vomit?"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cannabinoid",
          "context": "Cannabinoid receptor signaling."
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase-4",
          "context": "Inhibition of phosphodiesterase-4 decreases ethanol intake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "decreases ethanol intake in mice."
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases ethanol intake",
          "context": "Inhibition of phosphodiesterase-4 decreases ethanol intake in mice."
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug reward",
          "context": "Neurocircuitry of drug reward."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "modulate cocaine-induced place preference in mice."
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine-induced place preference",
          "context": "modulate cocaine-induced place preference in mice."
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "Prevention of methamphetamine-induced behavioral sensitization"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral sensitization",
          "context": "methamphetamine-induced behavioral sensitization in rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP phosphodiesterase inhibitor",
          "context": "by a cyclic AMP phosphodiesterase inhibitor, rolipram."
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "by a cyclic AMP phosphodiesterase inhibitor, rolipram."
        },
        {
          "entity_type": "Compound",
          "entity_name": "type IV phosphodiesterases",
          "context": "The involvement of type IV phosphodiesterases in cocaine-induced sensitization"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "in cocaine-induced sensitization and subsequent pERK expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine-induced sensitization",
          "context": "in cocaine-induced sensitization and subsequent pERK expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP-specific phosphodiesterase",
          "context": "Comparison of cAMP-specific phosphodiesterase mRNAs distribution"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "Learning mechanisms in addiction: synaptic plasticity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "exposure to drugs of abuse."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP-specific phosphodiesterase 4",
          "context": "Lack of cyclic AMP-specific phosphodiesterase 4 activation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "naloxone",
          "context": "during naloxone-precipitated morphine withdrawal in rats."
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "naloxone-precipitated morphine withdrawal in rats."
        },
        {
          "entity_type": "Effect",
          "entity_name": "morphine withdrawal",
          "context": "naloxone-precipitated morphine withdrawal in rats."
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4",
          "context": "Blockade of phosphodiesterase 4 reverses morphine-induced ventilatory disturbance"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "reverses morphine-induced ventilatory disturbance without loss of analgesia."
        },
        {
          "entity_type": "Effect",
          "entity_name": "morphine-induced ventilatory disturbance",
          "context": "reverses morphine-induced ventilatory disturbance without loss of analgesia."
        },
        {
          "entity_type": "Effect",
          "entity_name": "analgesia",
          "context": "without loss of analgesia."
        },
        {
          "entity_type": "Compound",
          "entity_name": "type IV phosphodiesterase inhibitors",
          "context": "The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram,"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ro 20-1724",
          "context": "The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram,"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "Ro 20-1724 and rolipram, block the initiation of cocaine self-administration."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "block the initiation of cocaine self-administration."
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "block the initiation of cocaine self-administration."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP-specific phosphodiesterase inhibitor",
          "context": "of the cAMP-specific phosphodiesterase inhibitor, rolipram and cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "cAMP-specific phosphodiesterase inhibitor, rolipram and cocaine on brain stimulation reward."
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "rolipram and cocaine on brain stimulation reward."
        },
        {
          "entity_type": "Effect",
          "entity_name": "brain stimulation reward",
          "context": "cocaine on brain stimulation reward."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 4",
          "context": "Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D1 receptor",
          "context": "enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase-4 inhibitor",
          "context": "The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "heroin-seeking behavior induced by cues or heroin priming in rats."
        },
        {
          "entity_type": "Effect",
          "entity_name": "heroin-seeking behavior",
          "context": "rolipram attenuates heroin-seeking behavior induced by cues or heroin priming"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase",
          "context": "comparison of phosphodiesterase mRNA distribution in human brain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase-4",
          "context": "Localization of phosphodiesterase-4 isoforms in the medulla"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibitors",
          "context": "The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "extinction of cocaine-induced conditioned place preference in mice."
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine-induced conditioned place preference",
          "context": "extinction of cocaine-induced conditioned place preference in mice."
        }
      ]
    }
  ],
  "total_entities": 288,
  "extraction_date": "2026-02-01T08:41:28.995288+00:00"
}